Kathleen Ruffolo
Family · Royal Oak, MINPI 1508412826
Payments from drug & device makers
Across 35 payments — averaging $58.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Axonics, Inc.$136
- Novo Nordisk$124
- C. R. Bard, Inc. & Subsidiaries$94
- Nevro Corp.$68
- Scilex Pharmaceuticals Inc.$66
- plus $101 from 3 others
What the payments were for
- Travel & lodging$99849%
- Food & beverage$1,01150%
- Education$271%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 16 | $1,448 |
| Axonics, Inc. | 1 | $136 |
| Novo Nordisk | 1 | $124 |
| C. R. Bard, Inc. & Subsidiaries | 6 | $94 |
| Nevro Corp. | 3 | $68 |
| Scilex Pharmaceuticals Inc. | 3 | $66 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Urogen Pharma, Inc. | 1 | $33 |
| Averitas Pharma Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$917
- Axonics$136
- Wegovy$124
- INTELLIS ADAPTIVESTIM$119
How this compares
$2,036 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 21 | $17,653 |
| Estradiol | 78 | $4,713 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 31 | $278 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $65 |
| Cephalexin | 21 | $50 |
Paid to pharmacies, not to this prescriber.
Other family in Royal Oak
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.